Trial	Phase	Sponsor	Dist.
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	<1 mi
Study of COYA 302 for the Treatment of ALS	Phase 2/3	Coya Therapeutics	<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	<1 mi
Non-invasive BCI-controlled Assistive Devices	N/A	University of Texas at Austin	<1 mi
Multiple Sclerosis Implementation Network (Registry)	—	The University of Texas Health Science Center, Houston	<1 mi
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study	N/A	SetPoint Medical Corporation	<1 mi
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study	N/A	University of Texas at Austin	<1 mi
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis	Phase 3	Zenas BioPharma (USA), LLC	<1 mi
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis	Phase 3	Zenas BioPharma (USA), LLC	<1 mi
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years	Phase 2	ModernaTX, Inc.	<1 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis	Phase 3	Sanofi	<1 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis	Phase 3	Bristol-Myers Squibb	<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research	Phase 3	Oculis	<1 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	<1 mi
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS	N/A	The Methodist Hospital Research Institute	<1 mi
Care in Multiple Sclerosis (MS)	—	NYU Langone Health	<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis	Phase 1	Amylyx Pharmaceuticals Inc.	<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	<1 mi
Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis	N/A	The University of Texas Health Science Center, Houston	<1 mi
NARCOMS Registry: A Multiple Sclerosis Registry	—	University of Texas Southwestern Medical Center	<1 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	Phase 3	Novartis Pharmaceuticals	<1 mi
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation	N/A	The University of Texas at Dallas	13 mi
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity	Phase 2	Celgene	22 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.